Glatiramer acetate for the treatment of multiple sclerosis

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.4, 2004-04, pp. : 875-891

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glatiramer acetate in the treatment of multiple sclerosis

By Sela Michael Teitelbaum Dvora

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 7, 2001-07 ,pp. : 1149-1165

Informa Healthcare

Access to resources Recommend Favorite

The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment

By Messina Silvia Patti Francesco

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 10, 2013-10 ,pp. : 1349-1359

Informa Healthcare

Access to resources Recommend Favorite

Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis

By Ziemssen T.

Drug Safety, Vol. 24, Iss. 13, 2001-01 ,pp. : 979-990

Adis International

Access to resources Recommend Favorite

Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients

By Tsareva Ekaterina Y Kulakova Olga G Boyko Alexey N Shchur Sergey G Lvovs Dmitrijs Favorov Alexander V Gusev Evgeny I Vandenbroeck Koen Favorova Olga O

Pharmacogenomics, Vol. 13, Iss. 1, 2012-01 ,pp. : 43-53

Future Medicine

Access to resources Recommend Favorite

Glatiramer Acetate in the Treatment of Multiple Sclerosis: Emerging Concepts Regarding its Mechanism of Action

By Lalive Patrice H. Neuhaus Oliver

CNS Drugs, Vol. 25, Iss. 5, 2011-05 ,pp. : 401-414

Adis International

Access to resources Recommend Favorite